Compare UTF & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | ITGR |
|---|---|---|
| Founded | 2004 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2000 |
| Metric | UTF | ITGR |
|---|---|---|
| Price | $24.17 | $78.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 171.7K | ★ 594.6K |
| Earning Date | 01-01-0001 | 10-23-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.84 | 2.42 |
| Revenue | $138,636,669.00 | ★ $1,831,074,000.00 |
| Revenue This Year | N/A | $9.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.16 | $32.42 |
| Revenue Growth | ★ 19.80 | 9.54 |
| 52 Week Low | $22.05 | $62.00 |
| 52 Week High | $26.53 | $146.36 |
| Indicator | UTF | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 63.69 |
| Support Level | $23.59 | $77.30 |
| Resistance Level | $23.97 | $79.25 |
| Average True Range (ATR) | 0.26 | 2.04 |
| MACD | 0.05 | 1.05 |
| Stochastic Oscillator | 89.02 | 80.68 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.